INTRODUCTION {#S1}
============

Antigen-specific B cells proliferate and differentiate into antibody secreting cells (ASCs) or maintain the B cell program and become memory cells after infection or vaccination^[@R1],[@R2]^. The fate of responding B cells is tightly controlled by the expression levels of a network of transcription factors; Blimp-1, IRF4 and XBP-1 drive the differentiation of B cells into ASCs and induce the expression of the molecular machinery required for antibody secretion, whereas Pax5, IRF8 and Bcl-6 are among a set of transcription factors that help B cells maintain their identity^[@R3]^.

We previously demonstrated that a transient burst of antigen-specific ASCs could be detected in peripheral blood shortly after influenza vaccination and after influenza and dengue viral infections in humans^[@R4]--[@R6]^. Defining the phenotype of the ASC subset paved the way for our group and others to interrogate the repertoire of B cell responses in humans. ASCs have also been used to rapidly generate human monoclonal antibodies (mAbs) that can be utilized as therapeutics and for diagnostics^[@R6]--[@R8]^. In the past few years, the dynamics, magnitude, and specificity of the ASC response in peripheral blood after a variety of vaccinations and infections in humans have been extensively studied^[@R9]^.

Apart from ASCs, antigen-specific human memory B cells (MBCs) can also be detected in peripheral blood^[@R6],[@R10],[@R11]^. These memory cells are usually identified either indirectly by culturing peripheral blood mononuclear cells (PBMCs) under various conditions to drive their differentiation into ASCs, or by using fluorescently labeled antigens. In this study, we define a subset of antigen-specific B cells that is phenotypically, transcriptionally and functionally distinct from ASCs, that we refer to as activated B cells (ABCs). We demonstrate that ABCs could be detected in peripheral blood after influenza virus and Ebola virus infections and after influenza immunization in humans. Sequencing of antibody heavy chain (*IGH*) rearrangements showed that clones present among hemagglutinin (HA)-specific ABCs isolated at days 7 or 14 post-influenza immunization were detected in the MBC compartment three months after vaccination, at higher frequency than in pre-vaccination samples. The magnitude and duration of the ABC response compared to the ASC response was substantially larger when considered over the course of the infection or vaccination, indicating that ABCs may be a particularly useful population for capturing the comprehensive repertoire of vaccine-induced antigen-specific B cell responses.

RESULTS {#S2}
=======

Defining B cell subsets after influenza immunization {#S3}
----------------------------------------------------

We previously demonstrated that antigen-specific ASCs peak in peripheral blood around day seven post-influenza immunization in humans^[@R6]^. We wanted to examine whether any other subset of antigen-specific B cells distinct from ASCs could be detected in the blood after vaccination. We hypothesized that, similar to ASCs, all recently antigen-engaged B cells would be actively proliferating. We used CD71 as a surface marker to label proliferating peripheral blood B cells after immunization with the inactivated seasonal trivalent influenza vaccine (TIV). From the isotype-switched, proliferating B cells, defined as CD3^−^CD14^−^CD16^−^CD19^+^IgD^−^CD71^hi^ cells isolated 7 days after vaccination, we identified two subsets: CD38^hi^CD20^−^ and CD38^int-lo^CD20^hi^ cells ([Fig. 1a](#F1){ref-type="fig"}). Markers of the former population are typical of those of ASCs, while we referred to the other population as activated B cells or ABCs. Both populations were positive for Ki67, confirming that cells were dividing ([Fig. 1b](#F1){ref-type="fig"}).

We confirmed the identity and specificity of the ASC subset by direct *ex vivo* ELISPOT ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). The majority (\~82%) of IgG^+^ ASCs were antigen-specific. ABCs, however, did not spontaneously secrete antibodies under the same conditions ([Fig. 1c](#F1){ref-type="fig"}). ABCs differentiated into IgG-secreting cells when cultured in the presence of autologous CD19^−^ cells as feeders ([Fig. 1d](#F1){ref-type="fig"} and [Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}). Approximately 45% of the IgG^+^ ABCs were specific to influenza vaccine ([Fig. 1d](#F1){ref-type="fig"}).

Similar to ASCs, ABCs were larger in size compared to naïve B cells ([Fig. 1e](#F1){ref-type="fig"}). In contrast to ASCs, ABCs did not downregulate CD19 relative to naïve B cells ([Fig. 1e](#F1){ref-type="fig"}). ABCs showed higher expression of CD27 and lower expression of CD21 relative to naïve B cells (IgD^+^CD27^−^) ([Fig. 1e](#F1){ref-type="fig"}).

Down-regulation of the B cell transcription factor Pax5 is one of the earliest events of ASC differentiation^[@R12]--[@R14]^. Pax5 expression measured by intracellular staining and flow cytometry was significantly lower in ASCs in comparison to naïve B cells and ABCs ([Fig. 1f](#F1){ref-type="fig"}). In contrast, IRF4 expression was highest in ASCs compared to naïve B cells and ABCs ([Fig. 1g](#F1){ref-type="fig"}). IRF8 is a transcription factor that antagonizes plasma cell differentiation^[@R15]^. Similar to Pax5, IRF8 expression was significantly lower in ASCs in comparison to naïve B cells and ABCs ([Fig. 1h](#F1){ref-type="fig"}). These data demonstrate that following influenza immunization in humans, two functionally and phenotypically distinct antigen-specific B cell subsets can be detected in peripheral blood.

Detecting ABCs after influenza and Ebola virus infections {#S4}
---------------------------------------------------------

After characterizing ABCs following influenza vaccination, we sought to define this population after influenza infection. We examined cryopreserved PBMCs from two patients with confirmed 2009 pandemic H1N1 influenza virus infection^[@R16]^. Blood was first collected at the day of enrollment (Day 0) and at several time points thereafter (on or about days 4, 7, 11, and 27 after enrollment). At days 3 and 11 after enrollment, ASCs (CD20^−^CD71^+^) and ABCs (CD20^hi^CD71^+^) could be distinguished among isotype-switched B cells ([Fig. 2a](#F2){ref-type="fig"}).

B cell responses to influenza in adults are dominated by recall responses^[@R6],[@R17]^. We wanted to test whether we could detect ABCs and ASCs in blood in the course of a primary immune response in humans. We had the unique opportunity to examine the immune responses in four patients (EVD02, EVD05, EVD09 and EVD15) infected with the Ebola virus^[@R18],[@R19]^. The four patients were cared for in the Serious Communicable Diseases Unit at Emory University Hospital^[@R18],[@R19]^. Among CD19^+^ cells, we were able to clearly distinguish both ASCs (CD20^−^CD71^hi^) and ABCs (CD20^hi^CD71^+^) during the early phase of the infection ([Fig. 2b](#F2){ref-type="fig"}). A massive B cell response was observed in all patients approximately two to three weeks after onset of symptoms, with ABCs and ASCs comprising almost half of peripheral blood B cells in three out of the four patients ([Fig. 2b](#F2){ref-type="fig"}). The percentages of ABCs and ASCs (of CD19^+^ cells) were 14.8 and 29.3 in EVD02, 31.4 and 33.3 in EVD05, 14.4 and 36.8 in EVD09, and 16.2 and 4.14 in EVD15, respectively ([Fig. 2b](#F2){ref-type="fig"}). As the infection progressed, the percentage of B cells with the ABC phenotype increased while those with the ASC phenotype decreased ([Fig. 2c](#F2){ref-type="fig"}). These data clearly demonstrate that ABCs could be detected in peripheral blood shortly after viral infection in humans, including after primary infections. It also shows that ABCs can originate from memory B cells (influenza) or naïve B cells (Ebola).

ABCs are transcriptionally distinct from ASCs and MBCs {#S5}
------------------------------------------------------

To define the transcriptional program of ABCs, we analyzed the gene expression profile of ABCs and compared it with those of ASCs, naïve B cells and resting MBCs. We isolated these B cell populations by flow cytometry from four individuals seven days after immunization with the 2013/14 TIV ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Unsupervised hierarchical clustering showed that both proliferating B cell subsets (ABCs and ASCs) grouped differently from the resting ones (Naïve and MBCs) ([Fig. 3a](#F3){ref-type="fig"}). Importantly, the four ABC samples formed a distinct cluster, indicating that the differences in gene expression between ABCs and all other B cell subsets were sufficiently robust to be reproducible in the four individuals ([Fig. 3a](#F3){ref-type="fig"}).

Expression analysis revealed 192 genes that were differentially upregulated in the ABC subset ([Fig. 3b](#F3){ref-type="fig"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). A substantial number of these genes encode proteins that are involved in antigen presentation (for example, *HLA-DRA*, *HLA-DMA*, *HLA-DPA1*, *NCF2*, *CD1C* and *CTSH*), and in B cell antigen receptor (BCR) signaling (*CD19*, *RFTN1*, *CSK* and *PRKCB*). To validate the array results we examined the expression of some of these differentially expressed genes at the protein level ([Fig. 3c](#F3){ref-type="fig"}). Consistent with the array results, surface protein expression of CD20, TLR10 and CD52 was highest on ABCs ([Fig. 3c](#F3){ref-type="fig"}). Conversely, there were 760 genes differentially upregulated in ASCs ([Fig. 3b](#F3){ref-type="fig"}). These genes included *PRDM1*, *IRF4* and *XBP1*, which encode the key transcription factors that control ASC generation, maintenance, and antibody secretion. Genes encoding proteins involved in extracellular protein synthesis and secretion (*TRAM1*, *SEC61B* and *KDELR1*) were also substantially upregulated in ASCs ([Fig. 3b](#F3){ref-type="fig"}).

To better understand the interactions between these differentially expressed genes and to put them into biological context, we performed gene set enrichment analysis (GSEA) on pre-ranked gene lists using previously described Blood Transcription Modules (BTMs) as gene sets^[@R20],[@R21]^. This analysis confirmed that the differentially expressed genes in ABCs were mostly associated with antigen processing and presentation and BCR signaling ([Fig. 3d,e](#F3){ref-type="fig"}). Differentially expressed genes in ASCs were associated with a plasma cell signature and the molecular machinery essential for antibody secretion ([Fig. 3d](#F3){ref-type="fig"}). We next examined the genes that were differentially expressed between ABC and resting MBC subsets. We found that those genes were mainly associated with cell cycle regulation, antigen presentation, BCR signaling and MAP kinase signaling ([Fig. 3f](#F3){ref-type="fig"}). These data clearly demonstrate that ABCs represent a transcriptionally distinct subset from ASCs and resting MBCs.

Dynamics of influenza HA-specific B cell responses {#S6}
--------------------------------------------------

To further examine the specificity and dynamics of ABCs after influenza vaccination, we used the HA protein of influenza virus to label antigen-specific cells after seasonal influenza vaccination. The HA used was derived from the 2009 pandemic H1N1 virus (A/California/7/2009), which has been included as a component in all human seasonal influenza vaccines formulations since the 2009/10 season. Two populations of HA-binding cells were clearly identified among isotype-switched B cells seven days after vaccination: HA-positive CD20^−^ cells (or HA-positive ASCs) and HA-positive CD20^hi^ (or HA-positive ABCs) ([Fig. 4a--e](#F4){ref-type="fig"}). Lower HA binding intensity observed on HA-positive ASCs in comparison to HA-positive ABCs is probably a result of the lower density of surface BCR expression on ASCs compared to ABCs ([Fig. 4a](#F4){ref-type="fig"}). HA-positive ABCs were Pax5^hi^ and IRF4^lo^ while HA-positive ASCs were Pax5^lo^ and IRF4^hi^ ([Fig. 4b](#F4){ref-type="fig"}).

The identity and specificity of HA-positive ASCs was confirmed by *ex vivo* ELISPOT where more than 90% of the IgG-secreting cells were specific to the H1 HA ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). In contrast, no IgG-secreting cells were detected with sorted HA-positive ABCs confirming that they are not differentiated into ASCs ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). However, after culturing HA-positive ABCs, we found that 62% of these cells secreted HA-binding antibodies ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}).

At day 14, HA-positive ASCs were no longer detectable in blood. In contrast, the frequency of HA-positive CD20^hi^ isotype-switched B cells was highest at this time point ([Fig. 4c](#F4){ref-type="fig"}). Both HA-positive ASCs and HA-positive ABCs detected at day 7 showed high expression of the proliferation marker CD71 ([Fig. 4d](#F4){ref-type="fig"}). CD71 and CD20 expression remained relatively high on HA-positive ABCs at days 14 & 30 in comparison to naïve B cells ([Fig. 4d](#F4){ref-type="fig"}). Three months after vaccination, CD71 expression on HA-positive memory B cells was indistinguishable from that on naïve B cells ([Fig. 4d](#F4){ref-type="fig"}). We next examined the dynamics of HA-positive ABCs and HA-positive ASCs following influenza infection. Four days after enrollment, HA-positive ASCs (CD20^−^) and HA-positive ABCs (CD20^hi^) could be identified among isotype-switched B cells ([Fig. 4e](#F4){ref-type="fig"}). These data demonstrate that HA-positive ABCs and ASCs could be clearly distinguished in peripheral blood shortly after influenza vaccination and infection in humans.

HA-specific clones span ABCs and ASCs {#S7}
-------------------------------------

We next wanted to determine whether similar or distinct B cell clones constitute the ABC and ASC compartments isolated after influenza vaccination. To address this question, we sequenced the immunoglobulin heavy chain (*IGH*) genes from HA-positive and HA-negative ABCs at days 7 and 14, and from ASCs isolated at day 7 (peak of ASC response) from three donors following immunization with the 2014/15 seasonal TIV ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Down-regulation of surface Ig expression in differentiating ASCs likely results in underestimation of the number of antigen-specific cells. Approximately 90% of IgG-secreting ASCs from day 7 are specific to TIV by ELISPOT (data not shown), therefore we considered IgG lineages from the ASC pool to be representative of the vaccine-induced clonal lineages in subsequent analyses. B cell clonal lineages were defined by *IGH* rearrangements that shared variable and joining gene segment usage (referred to hereafter as *IGHV* and *IGHJ*), and encoding complementarity-determining region 3 (CDR3) of equal length and similar CDR3 nucleotide sequence, clustering at a 90% identity threshold using single linkage clustering.

An average of 33% (range: 20.1% -- 41%) of the day 7 HA-positive ABC clonal lineages were also present among day 7 IgG^+^ ASCs, while 20% (range: 10.4% -- 26.7%) of the day 14 HA-positive ABC clonal lineages were detected in day 7 IgG^+^ ASC clonal lineages ([Fig. 5a](#F5){ref-type="fig"}, top). H1 HA-positive ABCs represent only a fraction of the total response to all the different antigens derived from the three influenza strains (H1N1, H3N2 and influenza B) included in seasonal TIV preparations. Therefore, we also examined the clonal overlap between total (HA-positive and HA-negative) ABCs and IgG^+^ ASCs. Among total ABC clonal lineages, we found that 34.4% (range: 21.8% -- 52.6%) of day 7 ABCs, and 24% (range: 16% -- 29.1%) of day 14 ABCs were present in the day 7 IgG^+^ ASCs ([Fig. 5a](#F5){ref-type="fig"}, bottom). These data show that many B cell clones have members in both of these two distinct phenotypic subsets, but the majority of clones are found in one subset only.

We next determined the frequency of each of the clonal lineages within the ABC and ASC pools. The clone frequencies within each pool were positively correlated, suggesting that the extent of clonal expansion in each compartment was similar ([Fig. 5b](#F5){ref-type="fig"}). The accumulation of somatic hypermutations (SHMs) in the antibody *IGH* rearrangement provides information about the cell division history within a clonal lineage. The average *IGHV* SHM frequency within responding ASCs and ABCs was 7% and 6.5%, respectively ([Fig. 5c](#F5){ref-type="fig"}). These ABC and ASC SHM frequencies were similar to those observed among pre-existing memory B cells, suggesting that MBCs are the likely precursors for both cell subsets. We then assessed the SHM frequencies within the clonal lineages shared between the ABC and ASC pools, and as shown in [Fig. 5c](#F5){ref-type="fig"} the SHM frequencies were strikingly similar between the two compartments. This match in SHM frequencies was observed regardless of the extent of SHM frequency ([Fig. 5c](#F5){ref-type="fig"}). Collectively, these data suggest that part of the vaccine-induced ABC and ASC clonal lineages have originated from the same memory B cells and later diverged into distinct fates.

HA-specific ABCs are clonally related to MBCs {#S8}
---------------------------------------------

To determine the fate of ABCs, we tracked ABC clonal lineages for three months following TIV vaccination in two separate cohorts ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). In the first cohort we sorted total ABCs and ASCs from three donors seven days after immunization with the 2013/14 TIV. We also sorted HA-positive ABCs from day 14 (peak of ABC expansion). To gather mutational data from additional B cell clone members, we analyzed the *IGH* repertoire within total PBMCs from day 0 (before vaccination) and days 28 and 90 post-vaccination. We tracked HA-positive clonal lineages (sorted at day 14) at various time points ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). A relatively small percentage (average 1%, range: 0.34% -- 2%) of the HA-positive day 14 ABC lineages were detectable prior to vaccination. This percentage increased at one-week post-vaccination; an average of 11.6% (range: 4.4% -- 23.3%) of the HA-positive day 14 ABC lineages were detectable among D7 ABC lineages ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). 10% and 8.8% of day 14 HA-positive ABC clonal lineages persisted in peripheral blood and were detectable at days 28 and 90 post-vaccination, respectively, suggesting that these clones had now become part of the resting MBC population ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}).

To further explore the kinetics and clonal relationship between ABC and resting MBCs in humans after influenza vaccination, we analyzed the corresponding repertoires in three additional donors during the 2014/15 influenza season. HA-positive ABCs were sorted from days 7 and 14, as well as MBCs from day 0 and days 14, 28 and 90 after vaccination ([Fig. 6a](#F6){ref-type="fig"} and [Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}). HA-positive clonal lineages present in the ABC populations were found to persist as resting memory B cells, with an average of 36.25% (range: 12 -- 55.6%) of day 7 HA-positive ABC lineages and an average of 26.7% (range: 21.5 -- 36.0%) of day 14 HA-positive ABC lineages detected at day 90 after vaccination ([Fig. 6a,b](#F6){ref-type="fig"}). We examined the persistence of total ABC-derived lineages from day 7 and day 14, and found that the percentages of total ABC lineages still detectable at day 90 post-vaccination were similar to the percentages of HA-positive ABC lineages ([Fig. 6a,b](#F6){ref-type="fig"}). Both ASC and ABC lineages were detectable at a low percentage among pre-vaccination MBCs. An average of 11.7%, (range 4.6% -- 19.2%) of IgG^+^ ASC lineages, and 8%, (range 2.1% -- 12.1%) of day 14 ABC lineages were detected in the pre-vaccination memory pool ([Fig. 6a, b](#F6){ref-type="fig"}).

Importantly, the ABC and ASC clonal lineages were largely distinct from resting MBCs sorted at day 14 ([Fig. 6b](#F6){ref-type="fig"}). The percentage of total ABC lineages that included day 14 resting MBCs ranged from 0.3% (donors 4 and 8) -- 3.2% (donor 6). The frequency of HA-positive lineages in the day 14 resting MBC pool was very low, and ranged from 0.4% (donor 4) -- 4.7% (donor 6) ([Fig. 6b](#F6){ref-type="fig"}). The data, therefore, indicate that the ABC clones are enriched for vaccine-induced lineages, and that few members of these clonal lineages remain in a non-activated state in the blood at day 14 after vaccination. Taken together, our data clearly show that ABC clonal lineages contribute to the resting MBC population.

Minimal impact on SHM frequency by seasonal TIV vaccination {#S9}
-----------------------------------------------------------

We next wanted to investigate how the extent of SHM of HA-positive ABCs changes over time after seasonal TIV vaccination. To address this question we longitudinally tracked HA-positive ABC clonal lineages and then compared the SHM frequencies within the *IGHV* segments measured at various time points before and after vaccination. HA-positive ABCs substantially expanded from day 0 to day 7, and reached their peak at day 14 after vaccination ([Fig. 7a](#F7){ref-type="fig"}). From the six donors we analyzed, we did not detect any substantial differences in *IGHV* SHM frequencies measured prior to vaccination, early after vaccination (days 7 and 14) and those measured at day 90 ([Fig. 7b](#F7){ref-type="fig"} and [Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}). This result was consistent with the SHM frequencies of individual HA-positive ABC clonal lineages from donors 4 and 6 ([Fig. 7c, d](#F7){ref-type="fig"}), and from donors 157, 162, 163 and 8 ([Supplementary Fig. 7b](#SD1){ref-type="supplementary-material"}) measured at various time points before and after vaccination. The initial SHM frequency within individual HA-positive ABC clonal lineages did not seem to have an impact on whether the descendants of that particular lineage will gain more mutation at later time points after vaccination. For example, all five HA-positive ABC clonal lineages tracked from baseline to day 90 after vaccination in donor 4 did not substantially gain any increase in SHM frequency despite the differences in their starting frequencies ([Fig. 7c](#F7){ref-type="fig"}). Longitudinal tracking of HA-specific ABC clones revealed minimal gain in SHM following seasonal influenza immunization.

DISCUSSION {#S10}
==========

Memory B cells and long-lived plasma cells provide a remarkably stable humoral immune memory that can last for a lifetime^[@R22],[@R23]^. Appropriate induction of both cell populations is therefore essential for optimal efficacy of prophylactic vaccines. Plasmablasts or ASCs in peripheral blood following infection and vaccination of humans have recently been extensively characterized^[@R9]^. In the current study we define an antigen-specific human activated B cell subset (referred to as ABCs) that is phenotypically, transcriptionally and functionally distinct from ASCs. ABCs could be detected within seven days of influenza vaccination in adults, and shortly following influenza and Ebola viral infections. High-throughput sequencing of the ABC immunoglobulin gene repertoire allowed us to track ABC clonal lineages, revealing that these lineages persisted in peripheral blood up to 90 days after vaccination (the latest time point measured in these experiments), suggesting that ABCs contribute to the memory B cell pool. Similar to ASCs, ABCs could be used for unbiased interrogation of the antigen-specific B cell repertoire following infection and vaccination of humans, and also as a source for procuring therapeutic mAbs. These ABC-derived mAbs may differ from those derived from ASCs in terms of quality and specificity^[@R24]^.

20--30% of the ABC clonal lineages are shared with the ASC compartment, indicating that while some clones adopt both phenotypes, it may be more common for individual clones to be polarized to an ASC or ABC phenotype in a vaccine response. This percentage could be an underestimate due to the limited number of individual B cell members of antigen-specific clones that are captured in the volume of blood sampled for research studies. In our previous influenza vaccination and infection studies^[@R4],[@R6],[@R17]^ we reported that antigen-specific IgG-secreting cells that possessed high *IGH* SHM frequencies dominated the ASC response, and attributed this result to the likely MBC origin of these ASCs. Here, we show that HA-positive ABC lineages possessed SHM loads similar to both ASCs and to the pre-vaccination MBC pool, suggesting that ABCs are also derived from MBCs. This notion was confirmed by tracking of HA-positive lineage members from the pre-vaccination MBC compartment into the post-vaccination ABC, ASC and MBC populations.

Memory B cells, by definition, are quiescent^[@R25]^. This is why we make the distinction between the Ki67^+^ and CD71^hi^ ABC subset and resting MBCs. This is consistent with our observation that very few ABC clonal lineages were detectable in the resting MBC compartment isolated at day 14 after vaccination. Conversely, starting from days 28 and 90 after vaccination (after the immune reaction had subsided) we detected up to 60% of the ABC clonal lineages in the resting MBC compartment. The delayed kinetics of ABCs are consistent with previous reports demonstrating delayed peaking of antigen-specific MBCs in comparison to ASCs following tetanus and influenza immunization^[@R6],[@R26]^. This difference in timing following infection or vaccination may reflect a preference for the immune system to first rapidly generate ASCs whose antibodies directly engage the foreign antigens. ABCs could have greater capacity to mutate their BCRs as indicated by the higher expression of AID relative to ASCs (data not shown), however, we did not detect substantial mutational load differences between these two subsets. Overall, our data supports a model where antigenic stimulation drives naïve or resting memory B cells to undergo a rapid clonal expansion. Some of of the expanded cells terminally differentiate into ASCs. The rest of the progeny, ABCs, are released into the circulation more slowly. Over time ABCs down-regulate the activation markers, and join the resting MBC pool.

Perhaps the most intriguing finding in the current study is that the majority of responding B cell clones did not experience a substantial increase in SHM frequency over time following TIV immunization. These data suggest that while the tens of millions of seasonal influenza vaccine doses administered every year have the capability of boosting B cell responses quantitatively, the impact on the quality of these responses is minimal. One possible explanation is that the TIV-induced B cells could have originated from pre-existing MBCs with already high affinity receptors. Our cohorts were all adults with probable existing MBCs elicited by prior exposures to influenza antigens, such as the 2009 pandemic H1 HA, included in the seasonal influenza vaccine used in the current study. So perhaps the lack of novel epitopes being engaged by responding B cells has contributed to the minimal changes observed in SHM frequencies. Alternatively, the vaccine antigen amount may have been too limited to support a persistent germinal center reaction from which more highly mutated clones could have emerged. Finally, it is important to note that the TIV vaccine used was non-adjuvanted. It will be important to examine whether adjuvants could change the dynamics of affinity maturation associated with seasonal influenza vaccination in humans. Defining and studying ABCs along with ASCs in humans will reveal the intrinsic differences between the cells constituting these two compartments, which in turn would enhance our understanding of the longevity of vaccine-induced B cell responses.

Methods {#S11}
=======

Patients {#S12}
--------

All studies were approved by the Institutional Review Boards of Emory University, St. Jude Children's Research Hospital, the University of Tennessee Health Science Center/Le Bonheur Children's Hospital, and by the US Centers for Disease Control (CDC). Written consent was obtained from all patients. All work with Ebola specimens was performed in the CDC BSL-4 laboratory space. For the influenza vaccination studies, all subjects were healthy adults 18--49 years of age. Peripheral blood mononuclear cells (PBMCs) were isolated using Vacutainer tubes (BD) for immediate use or cryopreserved.

Vaccines {#S13}
--------

Trivalent, inactivated seasonal influenza vaccines or TIV (2012/13, 2013/14 and 2014/15 seasons) were obtained from Sanofi Pasteur Inc.

Antigens {#S14}
--------

For ELISPOT, we either used the TIV vaccine (diluted 1:20) or recombinant H1 HA protein derived from the pH1N1 (A/California/06/2009) influenza virus. HA was obtained from the Biodefense and Emerging Infections (BEI) research repository. For HA staining, we used the HA1 subunit from H1 HA of A/California/06/2009 (H1N1) that was expressed in 293 T cells. HA molecules were biotinylated using the EZ-Link Micro NHS-PEG4-Biotinylation kit (Thermo-Fisher). Excess biotin was removed using the Zeba Spin Desalting Columns (Pierce).

Flow cytometry and cell sorting {#S15}
-------------------------------

Flow cytometry analysis was performed using either fresh or cryo-preserved PBMCs. For the Ebola samples, whole blood was incubated with appropriate surface antibody mix for 30 min then 1x FACS/Lyse (BD) was added to each sample. After a 5-min incubation, the sample was centrifuged to pellet cells and pellets were washed twice in PBS prior to data collection. For influenza vaccination and infection samples, PBMCs were resuspended in PBS supplemented with 2% FBS and 1mM EDTA. Cells were stained for 30 min at 4 °C for surface markers. For analyzing the intracellular IRF4, IRF8 and Pax5 molecules, cells were further fixed and permeabilized (eBioscience), and then incubated with antibodies for 1 h at 25°C. All reagents for flow cytometry staining are listed in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}. Flow cytometry data were analyzed using FlowJo software.

HA staining {#S16}
-----------

293 cells-expressed HA1 subunit of the pH1N1 H1 HA was biotinylated (EZ-Link™ Sulfo-NHS-Biotin, Life Technologies). PBMCs were incubated the biotinylated HA for 30 min at 4 °C prior to staining with APC-conjugated streptavidin.

ELISPOT and memory B cell assay {#S17}
-------------------------------

Direct ELISPOT to enumerate the number of either total IgG-secreting, vaccine-specific and recombinant HA-specific plasmablasts present in the PBMC samples. Basically, dilutions of washed PBMCs incubated in supplemented RPMI were incubated in ELISPOT plates for 18 h. After washing the plates, secreted antibodies were detected with anti-human IgG-biotin (Jackson ImmunoResearch) and avidin-D-HRP (Vector Laboratories) and developed with AEC substrate (Sigma) before analysis on an ELISPOT counter (Cellular Technologies Ltd.). Differentiation of ABCs to ASCs was done by culturing cells with autologous 10^5^ CD19^−^ PBMCs R-10 supplemented with phosphothiolated CpG ODN-2006, CD40L (R&D) and IL-21 (Peprotech). After culture for 6 d the cells were washed and quantified by ELISPOT assay.

Gene expression array {#S18}
---------------------

From four subjects, 10^4^ cells of either naïve B cells, memory B cells (MBCs), ABCs, ASCs were sorted seven days after influenza vaccination into RLT-Plus buffer (Qiagen). Total RNA was isolated using the Rneasy micro kit from Qiagen. After RNA amplification (Nugen), the genome-wide transcriptional profiles of both populations were assessed using the HumanHT-12 v4 Expression Bead Chip (Illumina). Data were quantile normalized before analysis.

Gene expression analysis {#S19}
------------------------

Hierarchical cluster analysis was performed using the top 15,000 probes with highest variance across all samples (Euclidean distance and Ward's criterion). To assess the uncertainty in cluster analysis, we run Pvclust R package with 5,000 bootstrap resampling^[@R27]^. To identify genes whose expression was specifically high in one B cell subset compared to others, we performed a student's *t*-test (*P* \< 0.05 and mean fold-change \> 1.5) between any given two cell subsets^[@R28]^. Genes were classified as highly expressed in one subset if they were up-regulated in this subset compared to at least 2 other subsets (out of 3 possible comparisons). We performed gene set enrichment analysis (GSEA) on pre-ranked gene lists using Blood Transcription Modules (BTMs) as gene sets. Expression of each gene across all samples was normalized by *z* score transformation and the mean *z* score of each subset was used to generate the pre-ranked gene lists. Probes representing the same gene symbol were collapsed by taking the *z* score with highest absolute value. Nominal *P*-values and normalized enrichment scores for the BTMs were generated running GSEA with 1,000 permutations. Cytoscape was used to display the gene network^[@R29]^.

Deep sequencing of *IGH* repertoires from influenza vaccine response {#S20}
--------------------------------------------------------------------

For the first cohort of vaccinees (2012--13 and 2013--14 seasons), RNA was purified with a Qiagen Rneasy micro kit from: 1) PMBCs from pre-vaccination, days 28 and 90 post-vaccination, 2) Flow sorted ASCs and ABCs isolated at day 7 post-vaccination, and 3) Flow sorted H1-specific ABCs isolated at day 14 post-vaccination. For the second cohort of vaccinees (2014--15 season) RNA was purified from: 1) PBMCs from pre-vaccination day 0, and post-vaccination days 7, 14, 28 and 90, 2) Flow sorted H1-positive and H1-negative ASCs and ABCs from day 7 post-vaccination, 3) Flow sorted HA-positive and HA-negative ABCs from day 14 post-vaccination, 4) Flow sorted memory B cells isolated prior to vaccination and at days 14, 28 (sorted for HA-positive and HA-negative) and 90 after vaccination, and 5) Naïve B cells flow sorted prior to vaccination. cDNA was synthesized with Superscript II enzyme (Life Technologies) and priming by random hexamers. Templates were amplified by PCR using Biomed IGHV primers in the framework 1 (FR1) region and isotype-specific primers for IgG, IgM and IgA located in the first exon of the constant regions. These primers also encoded approximately half of the Illumina linker sequences needed for cluster generation and sequencing on the Illumina MiSeq instrument. Sample identity was encoded by 8-nucleotide multiplex identifier barcodes in each primer. For Illumina cluster recognition, four randomized nucleotides were encoded in the primers immediately after the Illumina linker sequence in the constant region primers. Each antibody isotype for each sample was amplified in a separate PCR reaction, to prevent formation of cross-isotype chimeric PCR products. PCR was carried out with AmpliTaq Gold (Roche) following the manufacturer's instructions, and used a program of: 94°C 7 min, 35 cycles of (94°C 30 sec, 58°C 45 sec, 72°C 120 sec), and final extension at 72°C for 10 min. A second PCR step was used to add the remaining portion of the Illumina linkers to the amplicons, and was carried out with the Qiagen Multiplex PCR kit (Qiagen) according to the manufacturer's instructions, using 0.4 microliter of the first PCR product as template in a 30-microliter reaction. The PCR program for the second PCR step was 94°C 15 min, 12 cycles of (94°C 30 sec, 60°C 45 sec, 72°C 90 sec), and final extension at 72°C for 10 min. The products of each PCR reaction were quantitated, pooled in equimolar amounts, electrophoresed on agarose gels, and gel extracted with QIAquick kits (Qiagen). High-throughput sequencing was performed on an Illumina MiSeq instrument using 600-cycle sequencing kits.

Analysis of vaccine response *lGH* clonal lineages {#S21}
--------------------------------------------------

Paired-end reads from Illumina sequencing were merged using FLASH^[@R30]^ and samples were de-multiplexed according to the primer-encoded barcodes. Only exact, full-length matches to barcodes were permitted. Reads were aligned using a local installation of IgBLAST^[@R31]^ to determine features such as germline *IGHV*, *IGHD* and *IGHJ* gene usage, to define framework and complementarity determining regions and to identify mutation positions. Non-productive sequences that encoded either stop codons or had out-of-frame *IGHJ* were discarded from analysis, along with those that encoded CDR3 segments shorter than five residues (as these could not be reliably assigned to lineages). Antibody isotype subclasses were identified by exact matching to the CH1 sequence upstream of the primer used for amplification. For each donor, the clonal lineages were inferred from *IGH* rearrangements across the available samples by single linkage clustering of the CDR3 nucleotide sequences with a 90% identity threshold for *IGH* sequences that shared *IGHV* and *IGHJ* gene assignment (ignoring *IGHV* or *IGHJ* allele) and CDR3 length. HA-binding lineages were defined as clonal lineages for which a member in any phenotypic B cell subset was shown to bind HA in flow cytometry experiments; for lineages that had members detected in both HA-positive and HA-negative populations from flow sorting, we considered the lineage to be HA-binding if at least 10 reads were detected in the HA-positive samples, and at least 10% of total reads from the lineage in sorted cells were found in the HA-positive populations. IgG-expressing ASC lineages were defined as those containing members expressing IgG subtypes IgG1, IgG2 or IgG3. *IGHV* mutation percentages were calculated for the region spanning FR1 through the end of FR3. In summarizing *IGHV* mutation frequencies in B cell subsets, the mean mutation frequency was calculated for each B cell clone, then the median of these means over all clones was determined. The distribution of clonal lineage members across the different sample points was visualized using Circos^[@R32]^.

Statistics {#S22}
----------

Statistical analyses (described in context) were performed using GraphPad Prism and R.
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![Identification of antigen-specific ABCs and ASCs in peripheral blood after influenza vaccination in humans\
PBMCs isolated prior to- and seven days after immunization with the inactivated 2013/14 seasonal influenza vaccine (TIV). (a) A flow cytometry plot showing the gating strategy used to identify ABCs within B cells (CD3^−^CD14^−^CD16^−^CD19^+^). CD38^int-lo^ CD20^hi^ fraction of the IgD^−^ CD71^hi^ population represents ABCs. The CD38^hi^ CD20^−^ fraction represents the ASC subset. (b) Expression of the intracellular proliferation marker Ki67 as measured by flow cytometry in ABCs (blue), ASCs (red) and naïve B cells (grey). (c) *Ex-vivo* ELISPOT assay of day 7 ASCs. Mean percentages of TIV-specific IgG-secreting ASCs is shown (n = 3). N.D., not detectable. (d) Mean percentage of TIV-specific day 7 IgG-secreting ABCs (detected by ELISPOT) is shown (n = 3). ABCs were cultured for five days (see Methods) and then added on plates coated with either the TIV antigen or anti-human IgG. (e) Histogram plots showing the differences in forward scatter (FSC) and expression of CD19, CD27, and CD21 among ABCs (blue), ASCs (red) and naïve B cells (grey). (f-h) Expression of Pax5 (f), IRF4 (g) and IRF8 (h) in ABCs, ASCs and naïve B cells. Bar graphs show the mean of Pax5, IRF8 and IRF4 MFI in the three populations (n = 3). \*\*\* = *p*\<0.0001. *p*\<0.0001 (unpaired *t*-test (f--h)). Data represent at least two independent experiments.](nihms800610f1){#F1}

![Identification of ABC and ASC B cell subsets in blood after human influenza and Ebola virus infections\
(a) PBMCs taken from two H1N1-infected patients at the day of admission (day 0) as well as days 4, 11 and 27 after enrollment. FACS plots gated on isotype-switched B cells showing ABCs (CD20^hi^ CD71^hi^) and ASCs (CD20^lo^ CD71^hi^). (b) Whole blood samples were collected from a healthy donor and from four Ebola virus-infected patients, EVD02, EVD05, EVD09 and EVD15. FACS plots from the healthy donor and an acute phase time point (\~2--3 weeks after symptom onset) for each patient are depicted. Gated on CD19^+^ cells. (c) FACS plots of blood samples from EVD05 showing the kinetics of ABCs and ASCs at different days after symptom onset.](nihms800610f2){#F2}

![Gene expression array analysis of ABCs, ASCs, MBCs and Naïve B cells\
(a) Unsupervised cluster analysis using the top 15,000 probes with highest variance across all samples. Multiscale bootstrap resampling was used to calculate the "approximately unbiased" p-values for each branch (numbers in black, %). (b) Heat map of gene signatures of the four B cell subsets. Expression of genes (in rows), which were highly expressed in one subset is represented by the number of standard deviations above (red) or below (blue) the average value for that gene across all samples (in columns). Squares with dashed lines show selected genes highly expressed in ABCs (blue) and ASCs (red). (c) Box plots showing expression of *MS4A1*, *TLR10* and *CD52* in the four B cell subsets. Histogram plots showing surface protein expression of CD20, TLR10 and CD52 on the indicated B cell subsets. (d) GSEA analysis showing the Blood Transcription Modules whose expression activity is higher (red) or lower (blue) in one B cell subset compared to others (nominal p-value \< 0.01, see methods). Circle size ("corrplot" R package) is proportional to the nominal enrichment score (NES). (e) Genes in BTMs M28 and M54; each 'edge' (gray line) represents a coexpression relationship, as described in 1 colors represent the mean *Z* score for ABC samples (red = higher and blue = lower expression on ABCs compared to others). (f) A heat map showing fold increase (red) or decrease (blue) in gene expression between the ABCs and MBCs for selected pathways.](nihms800610f3){#F3}

![HA labeling of ABCs and ASCs in blood after influenza vaccination and infection\
PBMCs isolated from healthy adult volunteers prior to, and 7, 14, 30 and 90 days after immunization with the 2013/14 TIV. (a) A FACS plot gated on isotype-switched B cells showing HA-positive ASCs (CD20^lo^) and HA-positive ABCs (CD20^hi^). (b) Histogram plots showing expression of Pax5 and IRF4 in HA-positive ABCs, HA-positive ASCs, and naïve B cells. (c) A FACS plot (gated on isotype-switched B cells) showing the kinetics of HA-positive B cells after TIV immunization. (d) A FACS plot showing CD71 expression on HA-positive ASCs (red dots) and HA-positive ABCs/MBCs (blue dots) overlaid over naïve B cells (grey dots) (e) PBMCs isolated from an influenza-infected patient. FACS plots gated on isotype-switched B cells showing HA-positive ASCs (CD20^lo^) and HA-positive ABCs (CD20^hi^) at days 0, 4 and 27 after enrollment.](nihms800610f4){#F4}

![Comparing the B cell repertoires of ABCs and ASCs isolated after seasonal influenza vaccination\
(a) Pie charts show the percentage of HA-positive (2009 pandemic H1N1 HA) ABC (top) or total ABC (bottom) clonal lineages that were detectable in the IgG^+^ ASC compartment. The upper right segment of each pie is the percentage of ABC lineages, and the center indicates the total number of clonal lineages. (b) Correlation between clonal lineage size in IgG^+^ ASCs (day 7 post-TIV vaccination) and total ABCs (days 7 and 14 post-vaccination). (c) Correlation between the mean *IGHV* SHM frequency of IgG^+^ ASC clonal lineages (day 7 post-TIV vaccination) and total ABCs (days 7 and 14 post-vaccination). Each circle represents a clonal lineage; red-filled circles indicate HA-positive clonal lineages and unfilled circles indicate HA-negative lineages. Linear model regression lines are plotted in blue with standard error shaded in grey, and the coefficient of determination for the linear model (*r*^2^) and *P*-values are shown.](nihms800610f5){#F5}

![B cell repertoire sequencing of ABC, ASC and resting MBC lineages isolated before and after seasonal TIV\
(a) Clonal lineages shared between ABC, or ASC and pre- and post-vaccination MBC pools are indicated by ribbons linking arcs. Ribbon width represents the number of clonal lineages shared between subsets. The total number of clonal lineages for each subset is labeled and the arc color indicates the B cell subset and time point as specified in the legend. ABC and ASC arcs are zoomed 50X. (b) Percentage of ABC clonal lineages identified at either day 7 or day 14 post-vaccination that are also detected among resting MBC populations pre- or post-seasonal TIV.](nihms800610f6){#F6}

![*IGH* SHM frequencies of ABC lineages\
(a) Representative FACS plots (gated on isotype-switched B cells) showing the kinetics of HA-positive ABC/memory B cells following immunization with the 2014/15 TIV vaccine. PBMCs isolated at days 0, 7 14, 30 and 90 after vaccination are shown. (b) Longitudinal SHM frequencies of B cell clonal lineages that included HA-positive ABC members at day 14 post-vaccination with TIV during the 2014--15 season. Each point summarizes the median of the mean lineage *IGHV* SMH frequencies and bars show the 95% confidence interval. (c--d) Each panel represents the mean *IGHV* SHM frequency for different cell subsets and time points for individual clonal lineages from donor 4 (c) and donor 6 (d). The point color indicates the B cell subset and the point size indicates the number of sequencing reads for the lineage at a given time point. Linear regression lines are shown in blue.](nihms800610f7){#F7}
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